IDEAYA Biosciences Announces Option and License Agreement for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen August 7, 2024
Fixed-duration Calquence + venetoclax, with or without obinutuzumab, significantly improved PFS in 1L CLL in AMPLIFY Ph 3 trial August 7, 2024
PDUFA Action Date Extension Announced for Revumenib NDA for R/R KMT2Ar Acute Leukemia; new PDUFA action date: Dec 26, 2024 August 7, 2024
DARZALEX FASPRO® (daratumumab & hyaluronidase-fihj)-based quadruplet regimen approved in the US for patients with newly diagnosed transplant-eligible multiple myeloma August 7, 2024
IDeate-Lung02 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed SCLC August 7, 2024
Topline Data From ASPEN-06 Ph 2 Trial shows Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer August 7, 2024
FDA Fast Track Designation Granted to Ozuriftamab Vedotin (CAB-ROR2-ADC) for Patients with Recurrent or Metastatic SCCHN August 7, 2024
FDA grants Accelerated Approval to TECELRA® (afamitresgene autoleucel) for advanced MAGE-A4+synovial sarcoma in chemo-treated adults August 7, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
Boehringer Ingelheim secures novel immune checkpoint inhibitors with acquisition of Nerio Therapeutics August 7, 2024
Vir Biotechnology gets in Exclusive Worldwide License Agreement with Sanofi for Multiple Clinical-Stage T-cell Engagers August 7, 2024
Oncology programs CUE-101 and CUE-102 deprioritized to enhance focus on autoimmune program CUE-401 August 7, 2024
Vobramitamab Duocarmazine Update Provided; treatment recently discontinued for TAMARACK metastatic CRPC patients who remained eligible for further dosing August 7, 2024
Ph 2 Plans Announced for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review August 7, 2024
Alignment with FDA on Ph 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer August 7, 2024
Pivotal, adaptive MIRACLE Ph 3 trial designed for possible accelerated approval of Annamycin + cytarabine for the treatment of R/R AML August 7, 2024
